{
    "clinical_study": {
        "@rank": "55497", 
        "arm_group": [
            {
                "arm_group_label": "Transcranial pulsed electromagnetic fields (T-PEMF)", 
                "arm_group_type": "Active Comparator", 
                "description": "One group receives 8 weeks of active T-PEMF treatment and another group receives 8 weeks of placebo T-PEMF. Both treatments to be performed 30 minutes once a day."
            }, 
            {
                "arm_group_label": "Trancranial electromagnetic pulsed fields (T-PEMF)", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study, is to determine whether treatment using transcranial low voltage\n      pulsed electromagnetic fields (T-PEMF) can reduce the symptoms patients with Parkinson's\n      Disease (PD) experience. The symptoms include movement, mentality and the nervous system in\n      general.\n\n      Furthermore the purpose of this study is to clarify whether a group of patients with PD,\n      gain a statistical improvement in their symptoms when treated with active T-PEMF, compared\n      to a group of patients with PD who receive placebo T-PEMF ."
        }, 
        "brief_title": "Transcranial Low Voltage Pulsed Electromagnetic Fields (T-PEMF) in Patients With Parkinson's Disease", 
        "condition": "Parkinson Disease", 
        "condition_browse": {
            "mesh_term": "Parkinson Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with Idiopathic Parkinson's disease H & Y 1-3 (Hoehn&Yahr)\n\n          -  MMSE > 22 (a screening test for dementia). (MMSE - Mini-Mental State Examination)\n\n          -  Age > 18 years.\n\n          -  The patient is capable understanding, accepting and complete the planned procedures.\n\n        Exclusion Criteria:\n\n          -  The patient has been using T-PEMF before.\n\n          -  Changes in anti-parkinson drug treatment within the last 6 weeks\n\n          -  Noticeable dementia or other brain injury, which may affect the ability to give\n             consent, or   complicates the assessment of the patient\n\n          -  Psychosis, or other psychopathological conditions, which requires intervention\n\n          -  The abuse of alcohol or drugs\n\n          -  Treatment with Deep Brain stimulation.\n\n          -  Pregnancy or nursing\n\n          -  Epilepsy.\n\n          -  Active implants such as pacemakers and others for example cochlear implants\n\n          -  Active medical device for example insulin pumps, baclofen pumps.\n\n          -  Participation in other trials in the intervention period\n\n          -  Current or previous history of brain tumors, leukemia, malignant melanoma, skin\n             cancer, or head and neck cancer\n\n          -  Autoimmune disease\n\n          -  Wounds in the scalp"
            }, 
            "gender": "Both", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "April 23, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02125032", 
            "org_study_id": "T-PEMF14", 
            "secondary_id": "CIV-14-01-011780"
        }, 
        "intervention": [
            {
                "arm_group_label": "Transcranial pulsed electromagnetic fields (T-PEMF)", 
                "intervention_name": "Transcranial low voltage pulsed electromagnetic fields (T-PEMF)", 
                "intervention_type": "Device", 
                "other_name": "The device name is: Re5 - Parkinson Treatment System"
            }, 
            {
                "arm_group_label": "Trancranial electromagnetic pulsed fields (T-PEMF)", 
                "intervention_name": "Placebo Transcranial low voltage electromagnetic fields", 
                "intervention_type": "Device", 
                "other_name": "The devise name is: Re5 - Parkinson Treatment System"
            }
        ], 
        "lastchanged_date": "April 24, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Odense C", 
                    "country": "Denmark", 
                    "state": "Funen", 
                    "zip": "5000"
                }, 
                "name": "OUH Odense University Hospital"
            }
        }, 
        "location_countries": {
            "country": "Denmark"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "Denmark: Danish Health and Medicines Authority"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Comment on \"Title\": It is expected that the outcome measure UPDRS will report a change after 8 weeks of treatment compared to baseline.\nComment on \"Time Frame\": Data will be assessed at each group after 8 weeks, and will be presented when all included patients have received their intervention.", 
            "measure": "Change from baseline in Unified Parkinson\u00b4s Disease Rating Scale (UPDRS)", 
            "time_frame": "At baseline and at endpoint at week 8."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02125032"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Odense University Hospital", 
            "investigator_full_name": "Bo Mohr Morberg", 
            "investigator_title": "MD, Ph.D. student", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Odense University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Odense University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "study_design": "N/A", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}